Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood|
- Mutational status of the EGFR pathway [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2005|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Patients with lung cancer
Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
- Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
- Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.
OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899405
|United States, California|
|University of California Davis Cancer Center||Recruiting|
|Sacramento, California, United States, 95817|
|Contact: Clinical Trials Office - University of California Davis Cancer 916-734-3089|
|Principal Investigator:||Philip C. Mack, PhD||University of California, Davis|